Current pharmacologic treatment of elevated serum cholesterol.
- 1 September 1987
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 76 (3), 529-533
- https://doi.org/10.1161/01.cir.76.3.529
Abstract
A basic difference between dietary and drug therapy of hypercholesterolemia is that dietary therapy can be used as part of a population strategy, whereas the decision to use drugs is always made on an individual basis. In each case, the decision to treat must be based on the assumption that more good than harm is caused to the patient. This is a difficult situation for the physician. As long as there is no easy way of assessing the state and rate of progression of coronary lesions, the physician must treat the patient on statistical grounds only, i.e., rely on the results of studies showing that lowering serum cholesterol significantly decreases the risk of coronary events. Such evidence has recently been strengthened, which increases motivation for both physician and patients. The current general opinion is that drug therapy must be generally confined to those at high risk, i.e., patients with severe hypercholesterolemia. For individuals with moderately elevated serum cholesterol levels, dietary advice and correction of other risk factors should be adequate.Keywords
This publication has 20 references indexed in Scilit:
- A Receptor-Mediated Pathway for Cholesterol HomeostasisScience, 1986
- Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemiaThe American Journal of Cardiology, 1986
- Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.Journal of Clinical Investigation, 1984
- Reduction of Serum Cholesterol in Heterozygous Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1983
- Ciprofibrate in the therapy of type II hypercholesterolemia A double-blind trialAtherosclerosis, 1982
- Fenofibrate therapy of hyperlipoproteinaemia a dose—response study and a comparison with clofibrateAtherosclerosis, 1981
- Normalization of Low-Density-Lipoprotein Levels in Heterozygous Familial Hypercholesterolemia with a Combined Drug RegimenNew England Journal of Medicine, 1981
- Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesisAtherosclerosis, 1981
- Effects of Neomycin Alone and in Combination with Cholestyramine on Serum Cholesterol and Fecal Steroids in Hypercholesterolemic SubjectsJournal of Clinical Investigation, 1979
- NATURAL ŒSTROGEN AS AN EFFECTIVE TREATMENT FOR TYPE-II HYPERLIPOPROTEINÆMIA IN POSTMENOPAUSAL WOMENThe Lancet, 1978